Amazing. I’m stuck getting very expensive eye injections every four to five weeks, even with the latest Eylea HD.
March 29, 2026 at 4:48 PM
Amazing. I’m stuck getting very expensive eye injections every four to five weeks, even with the latest Eylea HD.
#Augen_auf #Fallbeispiel
Wir versuchen es (im 3. Post bitte Spielregeln lesen)
77j Patientin, laufende IVOM*-Therapie mit Eylea bei CNV**, letzte Injektion komplikationslos vor 5wo, nächste in 3 Wochen geplant. Letzter Visus 0,90, stellt sich vor mit "ich sehe seit gestern morgen schlecht"
Wir versuchen es (im 3. Post bitte Spielregeln lesen)
77j Patientin, laufende IVOM*-Therapie mit Eylea bei CNV**, letzte Injektion komplikationslos vor 5wo, nächste in 3 Wochen geplant. Letzter Visus 0,90, stellt sich vor mit "ich sehe seit gestern morgen schlecht"
#Augen_auf #Fallbeispiel
Ich möchte mal was ausprobieren. Keine Ahnung, ob das in diesem Format funktioniert, aber Versuch macht klug! Daher die Frage: Hättet Ihr Lust auf ein interaktives Fallbeispiel aus der Praxis? Ich stelle eine kurze Anamnese vor und dann tasten wir uns zur Diagnose/Therapie?
Ich möchte mal was ausprobieren. Keine Ahnung, ob das in diesem Format funktioniert, aber Versuch macht klug! Daher die Frage: Hättet Ihr Lust auf ein interaktives Fallbeispiel aus der Praxis? Ich stelle eine kurze Anamnese vor und dann tasten wir uns zur Diagnose/Therapie?
March 7, 2025 at 2:14 PM
#Augen_auf #Fallbeispiel
Wir versuchen es (im 3. Post bitte Spielregeln lesen)
77j Patientin, laufende IVOM*-Therapie mit Eylea bei CNV**, letzte Injektion komplikationslos vor 5wo, nächste in 3 Wochen geplant. Letzter Visus 0,90, stellt sich vor mit "ich sehe seit gestern morgen schlecht"
Wir versuchen es (im 3. Post bitte Spielregeln lesen)
77j Patientin, laufende IVOM*-Therapie mit Eylea bei CNV**, letzte Injektion komplikationslos vor 5wo, nächste in 3 Wochen geplant. Letzter Visus 0,90, stellt sich vor mit "ich sehe seit gestern morgen schlecht"
Überhaupt kein Problem! Und bitte direkt die nächste 3er Serie IVOM Termine mit Medikamentenwechsel auf Eylea mit neuer Unterschrift 🫠
October 2, 2025 at 11:54 AM
Überhaupt kein Problem! Und bitte direkt die nächste 3er Serie IVOM Termine mit Medikamentenwechsel auf Eylea mit neuer Unterschrift 🫠
I've been watching $REGN; Regeneron uses mAb garetosmab (activin/BMP blockade), siRNA cemdisiran and EYLEA HD VEGF-A exposure control - pipeline merits 35% rerate. I use @bluestocks.app analysi #finsky
September 27, 2026 at 8:01 PM
I've been watching $REGN; Regeneron uses mAb garetosmab (activin/BMP blockade), siRNA cemdisiran and EYLEA HD VEGF-A exposure control - pipeline merits 35% rerate. I use @bluestocks.app analysi #finsky
I went to get my monthly Eylea injection. In the waiting room was another patient hacking coughing the entire time. No mask, no covering his mouth. Someone came to take him to a private room.
May 4, 2026 at 11:17 PM
I went to get my monthly Eylea injection. In the waiting room was another patient hacking coughing the entire time. No mask, no covering his mouth. Someone came to take him to a private room.
Even fairytales have mirrors — and moments of courage.
Sight-saving Eylea injections today.
Resting now, eyes sore but I’m grateful for the treatment.
Back to wings and wonder soon.
Thank you for the warmth and kindness — it helps light the way.
Sight-saving Eylea injections today.
Resting now, eyes sore but I’m grateful for the treatment.
Back to wings and wonder soon.
Thank you for the warmth and kindness — it helps light the way.
A little pause in our fairytale world today 🧚
Real-life pages are turning too.
Thank you for all the warmth after yesterday’s wild-fairytale news —
I’m holding your kind words close as I head to Southampton Hospital
for eye injections this afternoon.
So replies may be quiet for a bit. #FairytaleMe
Real-life pages are turning too.
Thank you for all the warmth after yesterday’s wild-fairytale news —
I’m holding your kind words close as I head to Southampton Hospital
for eye injections this afternoon.
So replies may be quiet for a bit. #FairytaleMe
October 30, 2025 at 7:56 PM
Even fairytales have mirrors — and moments of courage.
Sight-saving Eylea injections today.
Resting now, eyes sore but I’m grateful for the treatment.
Back to wings and wonder soon.
Thank you for the warmth and kindness — it helps light the way.
Sight-saving Eylea injections today.
Resting now, eyes sore but I’m grateful for the treatment.
Back to wings and wonder soon.
Thank you for the warmth and kindness — it helps light the way.
i never did a xog eylea?????
March 31, 2025 at 12:40 PM
i never did a xog eylea?????
If anyone knows where the medicine lucentis eylea can be found in Gaza, please advise. I've been reaching out to medical charities today because Ahmad's mother needs it but there is none at the hospital. She also needs food and clean water, so financial help is very much welcome too. 🍉💉
May 5, 2026 at 3:25 PM
If anyone knows where the medicine lucentis eylea can be found in Gaza, please advise. I've been reaching out to medical charities today because Ahmad's mother needs it but there is none at the hospital. She also needs food and clean water, so financial help is very much welcome too. 🍉💉
Optical Coherence Tomography? I have some experience with that, and Eylea injections.
May 8, 2025 at 6:02 PM
Optical Coherence Tomography? I have some experience with that, and Eylea injections.
EyePoint's Duravyu hits its Phase 2 primary endpoint, aiming to rival Regeneron's Eylea.
EyePoint shares more mid-stage data for therapy trying to compete with Regeneron's Eylea
EyePoint's Duravyu meets primary endpoint in Phase 2 DME trial, showing potential to compete with Regeneron's Eylea and Roche's Vabysmo in the eye disease market.
endpts.com
February 5, 2025 at 6:35 PM
EyePoint's Duravyu hits its Phase 2 primary endpoint, aiming to rival Regeneron's Eylea.
Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal kickbacks through a charity to promote the use of its expensive eye drug Eylea reut.rs/418iJOi
February 20, 2025 at 1:09 AM
Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal kickbacks through a charity to promote the use of its expensive eye drug Eylea reut.rs/418iJOi
45 product candidates in $REGN ’s pipeline but it’s still priced like Eylea and Dupixent are the entire company and every incremental dollar invested will get torched.
Time horizons getting shorter these days. Sets up great dislocations for anyone with flexibility and duration.
Time horizons getting shorter these days. Sets up great dislocations for anyone with flexibility and duration.
October 28, 2025 at 1:55 PM
45 product candidates in $REGN ’s pipeline but it’s still priced like Eylea and Dupixent are the entire company and every incremental dollar invested will get torched.
Time horizons getting shorter these days. Sets up great dislocations for anyone with flexibility and duration.
Time horizons getting shorter these days. Sets up great dislocations for anyone with flexibility and duration.
These people can get fucked. Hope your ophthalmologist has plentiful stock of Eylea samples on hand and no other retina injection patients, otherwise good luck to you; may you forever feel the ramifications of voting for draconian policy.
July 4, 2025 at 11:32 AM
These people can get fucked. Hope your ophthalmologist has plentiful stock of Eylea samples on hand and no other retina injection patients, otherwise good luck to you; may you forever feel the ramifications of voting for draconian policy.
Eylea for macular degeneration
March 2, 2025 at 2:36 PM
Eylea for macular degeneration
Bronte comments on Eylea and Dupixent, and corresponding slides in Regeneron $REGN 25Q1 results presentation
NB. We have never published research on human* pharma businesses, and there is a reason for that
(*Animal pharma like Zoetis $ZTS is fine)
NB. We have never published research on human* pharma businesses, and there is a reason for that
(*Animal pharma like Zoetis $ZTS is fine)
June 1, 2025 at 7:19 AM
Bronte comments on Eylea and Dupixent, and corresponding slides in Regeneron $REGN 25Q1 results presentation
NB. We have never published research on human* pharma businesses, and there is a reason for that
(*Animal pharma like Zoetis $ZTS is fine)
NB. We have never published research on human* pharma businesses, and there is a reason for that
(*Animal pharma like Zoetis $ZTS is fine)
Regeneron got another FDA rejection for odronextamab and expects delays for Eylea HD. Regeneron also forecasts pending PDUFAs for Eylea HD could be delayed.
Regeneron gets another CRL, predicts delayed August PDUFA for Eylea HD
Regeneron's bispecific antibody has been rejected for the second time, and the drugmaker expects delays to other pending FDA approvals for Eylea HD, it said during a second-quarter earnings announceme...
endpoints.news
August 1, 2025 at 3:42 PM
Regeneron got another FDA rejection for odronextamab and expects delays for Eylea HD. Regeneron also forecasts pending PDUFAs for Eylea HD could be delayed.
Ophthopedia Update: Biocon launches aflibercept biosimilar Yesafili: Editor’s note: This is a developing news story. Please check back soon for updates.
Yesafili, an interchangeable biosimilar to Eylea 2 mg, is now commercially available in the United States, according to a press release from…
Yesafili, an interchangeable biosimilar to Eylea 2 mg, is now commercially available in the United States, according to a press release from…
Biocon launches aflibercept biosimilar Yesafili
Editor’s note: This is a developing news story. Please check back soon for updates.
Yesafili, an interchangeable biosimilar to Eylea 2 mg, is now commercially available in the United States, according to a press release from Biocon.
The FDA approved Yesafili (aflibercept-jbvf) in May 2024. It is indicated for neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy.
In the phase 3 INSIGHT study, researchers compared Yesafili with Eylea 2 mg (aflibercept, Regeneron) in patients with DME. There were no differences
dlvr.it
August 3, 2026 at 5:50 PM
Ophthopedia Update: Biocon launches aflibercept biosimilar Yesafili: Editor’s note: This is a developing news story. Please check back soon for updates.
Yesafili, an interchangeable biosimilar to Eylea 2 mg, is now commercially available in the United States, according to a press release from…
Yesafili, an interchangeable biosimilar to Eylea 2 mg, is now commercially available in the United States, according to a press release from…
The EYLEA - HD DTC drug ad looks fully AI generated, lol
January 17, 2026 at 3:00 AM
The EYLEA - HD DTC drug ad looks fully AI generated, lol
All the TV News Channel ads: Tremfya, Dupixent, Ozempic, Ubrelvy, Tepezza, Cosentyx, Skyrizzi, Eylea, Camzyos, Bimzelx, Qulipta, Arexvy, Rinvoq, Rexulti, Izervay, Vyvgart & Vyvgart Hytrulo, Wegovy, AustedoXR, Ingrezza, Sotyktu, Mounjaro, Vabysmo, Veozah, Vraylar, Breztri, Miebo, Evenity.
November 21, 2024 at 5:09 PM
All the TV News Channel ads: Tremfya, Dupixent, Ozempic, Ubrelvy, Tepezza, Cosentyx, Skyrizzi, Eylea, Camzyos, Bimzelx, Qulipta, Arexvy, Rinvoq, Rexulti, Izervay, Vyvgart & Vyvgart Hytrulo, Wegovy, AustedoXR, Ingrezza, Sotyktu, Mounjaro, Vabysmo, Veozah, Vraylar, Breztri, Miebo, Evenity.
eylea and jautumn sliiiiightly aged up for funsies (and a bigger projects)
March 20, 2025 at 9:40 AM
eylea and jautumn sliiiiightly aged up for funsies (and a bigger projects)
The FDA approved Dupixent for chronic hives after a prior rejection — but kept Eylea 8 mg capped at 16 weeks, denying Regeneron’s push for a 24-week label.
FDA approves Dupixent for hives, rejects new Eylea dosing schedule
FDA approves Dupixent (Regeneron/Sanofi) for chronic hives treatment but rejects extended dosing for Eylea.
endpts.com
April 21, 2025 at 2:08 PM
The FDA approved Dupixent for chronic hives after a prior rejection — but kept Eylea 8 mg capped at 16 weeks, denying Regeneron’s push for a 24-week label.
The Federal Circuit agreed with a lower court decision declining to temporarily block Amgen's biosimilar of Regeneron's blockbuster eye medication Eylea, affirming that court's application of claim construction precedent in the patent infringement suit. www.law360.com/artic...
Fed. Circ. Affirms No Block On Amgen's Eye Med Biosimilar - Law360
The Federal Circuit on Friday agreed with a lower court decision declining to temporarily block Amgen's biosimilar of Regeneron's blockbuster eye medication Eylea, affirming that court's application of claim construction precedent in the patent infringement suit.
www.law360.com
March 17, 2025 at 2:15 PM
The Federal Circuit agreed with a lower court decision declining to temporarily block Amgen's biosimilar of Regeneron's blockbuster eye medication Eylea, affirming that court's application of claim construction precedent in the patent infringement suit. www.law360.com/artic...
"New" could mean products that haven't yet launched, or which have launched recently (how recently?). But it probably excludes Eylea, a blockbuster first approved in 2011. Regeneron may also want to exclude Eylea HD, approved in 2023. But like other deals, most of the key info is not public. 2/2
April 24, 2026 at 3:30 PM
"New" could mean products that haven't yet launched, or which have launched recently (how recently?). But it probably excludes Eylea, a blockbuster first approved in 2011. Regeneron may also want to exclude Eylea HD, approved in 2023. But like other deals, most of the key info is not public. 2/2